A prospective randomized trial comparing low dose flutamide, finasteride, ketoconazole, and cyproterone acetate-estrogen regimens in the treatment ofhirsutism
S. Venturoli et al., A prospective randomized trial comparing low dose flutamide, finasteride, ketoconazole, and cyproterone acetate-estrogen regimens in the treatment ofhirsutism, J CLIN END, 84(4), 1999, pp. 1304-1310
Sixty-six hirsute women were randomized and treated with 1) flutamide (n =
15), 250 mg/day; 2) finasteride (n = 15), 5 mg/day; 3) ketoconazole (n = 16
), 300 mg/day; and 4) ethinyl estradiol (EE)cyproterone acetate (CPA; n = 2
0), 0.01 mg EE/day for the first week, 0.02 mg EE/day for the second week,
and 0.01 mg EE/day for the third week, followed by a pause of 7 days, then
12.5 mg CPA/day added during the first 10 days of every month for 12 months
. Hirsutism was evaluated by the Ferriman-Gallwey score, and hair diameter
and hair growth rate were determined by a special image analysis processor
in basal conditions and after 90, 180, 270, and 360 days of treatment. All
treatments produced a significant decrease in the hirsutism score, hair dia
meter, and daily hair growth rate: flutamide, -55 +/- 13%, -21 +/- 14%, and
-37 +/- 18%; finasteride, -44 +/- 13%, -16 +/- 12%, and -27 +/- 14%; ketoc
onazole, -53 +/- 18%, -14 +/- 12%, and -30 +/- 21%; and EE-CPS -60 +/- 18%,
-20 +/- 11%, and -28 +/- 21%.
Some differences existed among treatments with regard to effectiveness; EE-
CPA and flutamide seem to be the most efficacious in improving hirsutism. F
or the hirsutism scare, a greater decrease was seen with EE-CPA (-60 +/- 18
%) than with finasteride(-44 +/- 13%; P < 0.01) and a seater decrease was s
een with flutamide ( - 58 +/- 18% than with finasteride(-44 +/- 13%; P < 0.
05).
Flutamide is the fastest in decreasing hair diameter; EE-CPA is the fastest
in slowing down hair growth, even though at the end of the treatment there
was a significant difference between flutamide and finasteride only(-41 +/
- 18% vs. -27 +/- 14%; P < 0.05). Flutamide. ketoconazole, and EE-CPA induc
ed a significant decrease in total and free testosterone, 5 alpha-dihydrote
stosterone, dehydroepiandrosterone, dehydroepiandrosterone sulfate, and and
rostenedione plasma levels. During the EE-CPA treatment, gonadotropins were
suppressed, and the sex hormone-binding globulin level increased. Finaster
ide induced a decrease in dehydroepiandrosterone sulfate and 5 alpha-dihydr
otestosterone and an increase in testosterone levels.
Very few side-effects were observed during treatment with low doses of flut
amide, EE-CPA, and particularly finasteride. Flutamide induced a decrease w
hereas EE-CPA induced an increase in triglycerides and cholesterol, showing
higher values within the normal range. Ketoconazole induced several side-e
ffects and complications, and several people dropped out of the study.
Despite different modalities of action and significantly different effects
on androgen levers, low doses of flutamide, finasteride, and EE-CPA constit
ute very satisfactory alternative therapeutic regimens in the treatment of
hirsutism.